[ix][ix][ix]

Adda N et al. Evolution of clinical and laboratory features in patients with the HIV-associated lipodystrophy syndrome, treated by HAART regimens including amprenavir. Antivir Ther 5: S60, 2000.

Agrawal KC et al. Synergistic anti-adipogenic effects of HIV-1 protease inhibitors and TNF-alpha in 3T3-L1 cells: role of ECM degrading process. Antivir Ther 6: S18, 2001.

Agrawal KC et al. Highly active antiretroviral drugs modulate human aortic endothelial cell function: role of cell adhesion molecules, nitric oxide and reactive oxygen species. Antivir Ther 7: L8, 2002.

Amard P et al. The effects of polylactic acid as therapy for lipoatrophy of the face. Antiviral Therapy 5: S79, 2000.

Amaya RA et al. Lipodystrophy syndrome in human immunodeficiency virus-infected children. Pediatr Infect Dis J 21: 405-410, 2002.

Amellal P et al. Mitochondrial mtDNA content in peripheral blood mononuclear cells in naﶥ HIV-1 infected patients starting nucleoside analogues (NA). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, abstract H-164, 2004.

Anderson PL et al. The cellular pharmacology of nucleoside- and nucleotide analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis 38: 743-53, 2004.

Arpadi RS et al. Lipodystrophy in HIV-infected children is associated with high viral load and low CD4+ -lymphocyte count and CD4+ -lymphocyte percentage at baseline and use of protease inhibitors and stavudine. J Acquir Immune Defic Syndr 27: 30-34, 2001.

Aubron-Oliver C et al. Benefit of polylactic acid implant (New Fill) in severe facial lipoatrophy in HIV-infected patients: preliminary results of the Vega-Study. Eighth European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, abstract O20, 2001.

Babi FE et al. Abnormal body-fat distribution in HIV-infected children on antiretrovirals. Lancet 353: 1243, 1999.

Baldini F et al. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study. AIDS 14: 1660-1662, 2000.

Bani-Sadr F et al. HAART associated lipodystrophy: clinical score of severity and related immunovirological response. Third International Conference on Nutrition and HIV Infection, abstract P-8, 1999.

Barreiro P et al. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14: 807-812, 2000.

Barrios A et al. Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16: 2079-2081, 2002.

Bastard JP et al. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 359: 1026-1031, 2002.

Batterham MJ et al. Dietary intake, serum lipids, insulin resistance and body composition in the era of highly active antiretroviral therapy Diet FRS study. AIDS 14: 1839-1843, 2000.

Bauer JA et al. Endothelial toxicity induced by HIV protease inhibitors: evidence of oxidant related dysfunction and apoptosis. Pediatric Academic Societies' Annual Meeting abstract 2708, Baltimore, 2002.

Becker S et al. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA: results of a prospective, randomised, multicenter, open label study (DMP-266-049). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, abstract 20, 2000.

Behrens G et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: 63-70, 1999. Updated at the First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstracts 59 and 72, 1999.

Bentata-Pessayre M et al. Metabolic and morphologic tolerance of nevirapine in naive or pre-treated HIV1 infected patients. Thirteenth International AIDS Conference, Durban, abstract B4202, 2000.

Beregszaszi M et al. Longitudinal evaluation and risk factors of lipodystrophy and associated metabolic changes in HIV-infected children. J Acquir Immune Defic Syndr 40 (2): 161-168, 2005.

Berger DS et al. Factors contributing to new onset hypertension and coronary artery disease in persons with lipodystrophy and HIV disease. Third International Conference on Nutrition and HIV Infection, Cannes, abstract P-16, 1999.

Bernasconi E et al. Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy. AIDS 15: 1081-1082, 2001.

Bickel M et al. The Protra study: to evaluate the safety and efficacy of abacavir and efavirenz when substituted for a PI in HIV-1 infected subjects treated with 2 NRTIs and a PI with plasma HIV-RNA levels below the limit of assay quantification. Thirteenth International AIDS Conference, Durban, abstract B3210, 2000.

Boccara F et al. Stent implantation for acute left main coronary artery occlusion in an HIV-infected patient on protease inhibitors. J Invasive Cardiol 14: 343-346, 2002.

Bodary PF et al. Effect of leptin on arterial thrombosis following vascular injury in mice. JAMA 287: 1706-1709, 2002.

Bogner JR et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr 27: 237-244, 2001.

Bonnet E et al. Evolution of lipodystrophy syndrome and lipidic profile in HIV patients after switching from protease inhibitors to efavirenz. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 49, 2000.

Bonnet E et al. Short term impact of lipid lowering drugs (fibrates and statins) on lipid plasma levels in HAART-treated patients, Aquitaine Cohort, France, 1999-2001. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7353, 2002.

Boubaker K et al. Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study. Clin Infect Dis 33: 1931-1937, 2001.

Boufassa F et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treatment and immunovirological response. HIV Clin Trials 2: 339-345, 2001.

Bowers JM et al. Cardiac disease risk factors in a Veteran HIV+ population compared to the general USA population. Third International Conference on Nutrition and HIV Infection, Cannes, abstract P-16, 1999.

Bozzette SA et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 348: 702-710, 2003.

Brande J et al. Third Lipodystrophy Workshop, Athens, abstract P101, 2001.

Brinkman K et al. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 354: 1112-1115, 1999.

Brown T et al. Prevalence and incidence of pre-diabetes and diabetes in the Multicenter AIDS Cohort Study. Eleventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 73, 2004.

Brown TT et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Intern Med 165: 1179-1184, 2005.

Caldwell R et al. Evaluation of protease inhibitor associated hyperglycaemia in a university-based HIV clinic. Twelfth World AIDS Conference, Geneva, abstract 12395, 1998.

Calmy A et al. Leptin levels remain unchanged after pioglitazone treatment in HIV infected patients with lipodystrophy. Fourteenth International AIDS Conference, Barcelona, abstract TuPeB4524, 2002.

Calza L et al. Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART. AIDS 17: 851-859, 2003.

Calza L et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS 19: 1051-1058, 2005.

Calza L et al. Rosuvastatin for the treatment of hyperlipidaemia in HIV-infected patients receiving protease inhibitors: a pilot study. AIDS 19 (10): 1103 1105, 2005b.

Cammalleri C et al. The effects of protease inhibitors on basal and insulin-stimulated lipid metabolism, insulin binding, and signaling. J Lipid Res 44: 103-108, 2003.

Caron M et al. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance. Diabetes 50: 1378-1388, 2001.

Caron M et al. Stavudine and didanosine partly reversed the adverse effects of indinavir on cell differentiation and response to insulin but enhanced apoptosis of cultured adipocytes. Antiviral Therapy 7: L6 (abstract 9), San Diego, 2002.

Carr A et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353(9170): 2093-2099, 1999.

Carr A et al. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 14(3): F25-32, 2000.

Carr A et al. A HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 15(14): 1811-1822, 2001.

Carr A et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Journal of the American Medical Association 288(2): 207-215, 2002.

Carr A et al. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363 (9407): 429-438, 2004.

Chang K et al. Does race protect an oriental population from developing lipodystrophy in HIV-infected individuals on HAART? Journal of Infectious Diseases 44(1): 33-38, 2002.

Cheminot N et al. Diagnosis and determination of subclinical arterial disease in HIV 1-infected patients on HAART. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 31, 2000.

Chene G et al Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 34(5): 649-657, 2002.

Cheseaux JJ et al. Hyperlipidemia in HIV-infected children treated with protease inhibitors: relevance for cardiovascular diseases. Journal of Acquired Immune Deficiency Syndromes 30(3): 288-293, 2002.

Chow D et al. Epidemiologic evidence of increasing blood pressure in HIV-1 infected individuals in the era of HAART. Antiviral Therapy 5 (Supp 5): 31, 2000.

Christeff N et al. Changes in cortisol/DHEA ratio in HIV-infected men are related to immunological and metabolic perturbations leading to malnutrition and lipodystrophy. Annals of the New York Academy Sciences 917: 962-970, 2000.

Christeff N et al. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. AIDS 13(16): 2251-2260, 1999.

Clumeck N et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 15(12): 1517-1526, 2001.

Cohen C et al. Effect of nucleoside (NRTI) intensification on prevalence of morphological abnormalities (MoAs) at year 5 of ritonavir (RTV) plus saquinavir (SQV) therapy in an HIV-infected cohort. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 682, 2002.

Colson AE et al. Male sexual dysfunction associated with antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 30(1): 27-32, 2002.

Coplan P et al. Indinavir did not increase the short-term risk of adverse cardiovascular events relative to nucleoside reverse transcriptase inhibitor therapy in four phase III clinical trials. AIDS 15(12): 1584-1586, 2001.

Cormier K et al. Person-time analysis comparing rates of adverse events possibly related to increased lipids between nelfinavir and control patients in five clinical trials. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 61, 1999.

Cote HC et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. New England Journal of Medicine 346(11): 811-820, 2002.

Cotton G. Switching protease inhibitor to nevirapine leads to reversal of hyperlipidemia and lipodystrophy. Thirteenth International AIDS Conference, Durban, abstract B4197, 2000.

Cotton G. Sustained virological suppression in subjects switched from protease inhibitors to nevirapine. Thirteenth International AIDS Conference, Durban, abstract B4198, 2000.

Crane HM et al. Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy. AIDS 20: 1019-1026, 2006.

Cunney RJ et al. Reduced bone mineral density in HIV-positive men: association with protease-inhibitor therapy and low serum testosterone. 37th Annual Meeting of the Infectious Disease Society of America, Philadelphia, abstract 331, 1999.

Currier JS et al. A pilot study of carotid intima media thickness (IMT) in HIV-infected women treated with protease inhibitors. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 32, 2000.

Currier JS et al. Diabetes mellitus in HIV-infected individuals. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 677, 2002.

Currier J et al. Carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 131, 2003.

Currier JS et al. Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 19: 927-933, 2005.

Curry KM et al. Treatment of protease-associated hyperlipidemia with micronised fenofibrate. Fifth Annual Meeting of the British HIV Association, abstract P47, 1999.

The DAD Writing Committee. Cardio- and cerebrovascular events in HIV-infected persons. AIDS 18: 1811-1817, 2004.

Day TA et al. Comparison of the prevalence of lipodystrophy in HIV positive patients of different ethnicity. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract P131, 2000. AIDS 14(supp 4): p131, 2000.

Danoff A et al. Oral glucose tolerance and insulin sensitivity are unaffected by HIV infection or antiretroviral therapy in overweight women. J Acquir Immune Defic Syndr 39 (1): 55 - 62, 2005.

Del Pino V. Successful surgical therapy with polyvinyl gel microspheres of severe facial lipoatrophy: results after one year of follow up. Antiviral Therapy 6 (Supp 4):, 2001.

Depairon M et al. Noninvasive morphological analysis of carotid and femoral arteries in protease-inhibitor-treated HIV-infected individuals. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 29, 2000.

Dieleman JP et al. Substituting nevirapine for protease inhibitors because of intolerance. AIDS 13(11): 1423-1424, 1999.

Distler O et al. Direct effects of protease inhibitors on lipid metabolism in cultured mammalian cells. Antiviral Therapy 5 (Supp 5): 13, 2000.

Domingo P et al. Serum levels of soluble tumor necrosis factor (TNF) receptors correlate with the degree of infected patients with lipodstrophy. Fourteenth International AIDS Conference, Barcelona, abstract WePeA5792, 2002.

Domingo P et al. A randomized, double-blind, placebo-controlled, comparative study on the effects of metformin or gemfibrozil on markers of fibrinolysis and increased cardiovascular risk in HIV-infected patients with lipodystrophy. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7346, 2002b.

Dong BJ et al. Diabetes and use of protease inhibitors. Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 416, 1998.

Dressman J et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesterol accumulation in macrophages. Antiviral Therapy 7: L7 (abstract 11), 2002.

Driscoll SD et al. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. AIDS 18: 465 473, 2004.

Dube MP et al. Prospective evaluation of the effect of initiating indinavir-based therapy on insulin sensitivity and B-cell function in HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 27(2): 130-134, 2001.

Dube MP et al. Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy. Clinical Infectious Diseases 35(4): 475-481, 2002.

Dube MP et al. Prospective study of regional body composition in antiretroviral-naive subjects randomised to receive zidovudine + lamivudine or didanosine + stavudine combined with nelfinavir, efavirenz or both: A 5005s, a substudy of ACTG 384. Antiviral Therapy 7: L18 (abstract 27), 2002.

Duncombe C et al. Reversal of hyperlipidemia and lipodystrophy in patients switching therapy to nelfinavir. Journal of Acquired Immune Deficiency Syndromes 24(1): 78-79, 2000.

Duong KL et al. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy (HAART). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 21(2): 107-113, 1999.

Duong M et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 27(3): 245-250, 2001.

Duong M et al. Exercise stress testing for detection of silent myocardial ischemia in human immunodeficiency virus-infected patients receiving antiretroviral therapy. Clinical Infectious Diseases 34: 523-8, 2002.

Duran A et al. Prevalence of lipodystrophy and metabolic abnormalities in relation with antiretroviral regimens for the treatment of HIV infection. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 49, 1999.

Duran A et al. Prevalence of lipid abnormalities and osteoporosis related with antiretroviral (ARV) regimens in a general hospital of Buenos Aires. 37th Annual Meeting of the Infectious Disease Society of America, Philadelphia, abstract 356, 1999.

Engelson E et al. Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. American Journal of Clinical Nutrition 69(6):1162-1169, 1999.

Engelson ES et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. Journal of Acquired Immune Deficiency Syndromes 30(4): 379-391, 2002.

Engelson ES et al. The effects of diet and exercise weight loss program in obese HIV-infected women. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7339, 2002b.

Ermolieff J et al. Inhibition of coagulation factors by HIV protease inhibitors. International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, Virgin Islands, abstract 38, 1998.

Estrada V et al. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis 35: 69-76, 2002.

Estrada V et al. Leptin and adipose tissue maldistribution in HIV-infected male patients with predominant fat loss treated with antiretroviral therapy. J Acquir Immune Defic Syndr 29: 32-40, 2002b.

European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 18: 1443-1451, 2004.

Fabre J et al. Lipodystrophy syndrome and metabolic complications related to antiretroviral drugs. Thirteenth International AIDS Conference, Durban, abstract B4245, 2000.

Falutz J et al. Gender related differences in the lipodystrophy syndrome. Third International Conference on Nutrition and HIV Infection, abstract O-4, 1999.

Fauvel J et al. An interaction between apo C-III variants and protesae inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 15: 2397-2406, 2001.

Fellay J et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet 358: 1322-1327, 2001

Fessel J et al. Pivotal role for HDL cholesterol in central fat expansions of the fat redistribution syndrome. Thirteenth International AIDS Conference, Durban, abstract LB 115, 2000.

Fessel J et al. Effects of niacin upon fat expansion in HIV-positive patients who have the fat redistribution syndrome (FRS). Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 703, 2002.

Fichtenbaum CJ et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 16(4): 569-577, 2002.

Field M et al. HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 4(4): 327-38, 2004.

Fisac C et al. Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 19: 917-925, 2005.

Flynn TE et al. Myocardial infarction in HIV-infected men receiving protease inhibitors. Ann Intern Med 131: 548, 1999.

Ford ES et al. Vitamin supplement use and diabetes mellitus incidence among adults in the United States. Am J Epidemiol 153: 892-897, 2001.

Friis-Moller N et al. Exposure to HAART is associated with an increased risk of myocardial infarction: The DAD study. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 130, 2003.

Fumaz CR et al. Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens. J Acquir Immune Defic Syndr 29: 244-253, 2002.

Galli M et al. Risk of developing adipose tissue alterations after starting antiretroviral therapy in naive patients. Antiviral Therapy 5 (Supp 5): 59, 2000.

Galli M et al. Body habitus changes and metabolic alterations in protease inhibitor-naﶥ HIV-1 infected patients treated with two nucleoside reverse transcriptase inhibitors. Journal of Acquired Immune Deficiency Syndromes 29: 21-31, 2002.

Galli M et al. Triglyceridemia, but not choelsterolemia and glycemia, is a predictor of lipodystrophy: the results of LipoICONA longitudinal study. Antiviral Therapy 7: L29 (abstract 41), 2002b.

Gaou I et al. Effects of stavudine on mitochondrial DNA in mice. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract I-1628, 2000.

Garcia F et al. Incidence of metabolic changes and lipodystrophy in two trials comparing double versus triple antiretroviral therapy in early HIV Disease. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 58, 1999.

Garcia-Benayas T et al. Lipodystrophy body-shape changes in patient undergoing zidovudine monotherapy. AIDS 16(7): 1087-1089, 2002.

Garg A et al. Lipodystrophies. American Journal of Medicine 108(2): 143-152, 2000.

Gatell JM et al. One year effects of switching from HIV-1 PIs to nevirapine on metabolic abnormalities. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 40, 1999.

Gazzard B et al. Treatment with delavirdine in combination with nucleosides is not associated with lipodystrophy or metabolic lipid/glucose disorders. Third International Conference on Nutrition and HIV Infection, Cannes, abstract O-2, 1999.

Gelato MC et al. Improved insulin sensitivity and body fat distribution in HIV-infected patients treated with rosiglitazone: a pilot study. Journal of Acquired Immune Deficiency Syndromes 31(2): 163-170, 2002.

Gerber M et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract P726, 2003.

Germinario RJ et al. The long-term effects of anti-retroviral protease inhibitors on sugar transport in L6 cells. Journal of Endocrinology 178(3): 449-456, 2003.

Gervasoni C et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS 13(4): 465-471, 1999.

Gervasoni C et al. Long-term efficacy of the surgical treatment of buffalo hump in patients continuing antiretroviral therapy. AIDS 18: 574-576, 2004.

Gharakhanian S et al. Identification of fat redistribution/metabolic anomalies in a cohort treated by 2 NRTIs + 1 PI, and absence of significant modification following PI-substitution. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 46, 2000.

Goebel FD et al. Cardiovascular dysregulation in HIV-infected individuals treated with HAART. Antiviral Therapy 5 (Supp 5):17, 2000.

Goldmeier D et al. Does increased aromatase activity in adipose fibroblasts cause low sexual desire in patients with HIV lipodystrophy? Sexually Transmitted Infections 78(1): 64-66, 2002.

Gorgolas M et al. Efficacy of protease inhibitor switching to nevirapine in patients on HAART with undetectable viral load. Thirteenth International AIDS Conference, Durban, abstract B485, 2000.

Goujard C et al. Incidence of clinical lipodystrophy in HIV-infected patients treated during primary infection. AIDS 15(2): 282-284, 2001.

Greiger-Zanlungo P et al. Protease inhibitor-sparing regimens containing nevirapine, efavirenz, or abacavir achieve long-term HIV-1 aviremia and CD4 stabilization but do not improve metabolic complications. Fourteenth International AIDS Conference, Barcelona, abstract WePeB5901, 2002.

Griblin A et al. Progressive lipodystrophy in a protease inhibitor naﶥ woman with an undetectable viral load off ARV therapy. Fourth International Conference on Nutrition and HIV Infection, Cannes, abstract P32, 2001.

Grunfeld C et al. Hypertriglyceridaemia in the acquired immune deficiency syndrome. American Journal of Medicine 86: 27-31, 1989.

Grunfeld C. Fat derangements in patients on HAART therapy: hyperlipidemias and body habitus alterations, November 1998 AIDS Clinical Grand Rounds, reported in San Francisco General Hospital newsletter Synopsis, Jan, 1999a.

Grunfeld C. Metabolic toxicity of antiretroviral therapy explained. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999c.

Grunfeld C et al. Basic science and metabolic disturbances. Fourteenth International AIDS Conference, Barcelona, abstract TuOr158, 2002.

Hadigan C et al. Metformin in the treatment of HIV lipodystrophy syndrome. JAMA 284: 472-477, 2000.

Hadigan C et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 32: 130-139, 2001.

Hadigan C et al. Acute inhibition of lipolysis improves insulin sensitivity in patients with HIV lipodystrophy and insulin resistance, and Increased rates of lipolysis among HIV-infected men with and without fat redistribution. Antivir Ther 6: S7, 2001b.

Hadigan C et al. Modifiable dietary habits and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clinical Infectious Diseases 33: 710-717, 2001c.

Hadigan C et al. Effects of rosiglitazone on metabolic indices and fat in HIV lipodystrophy: a randomized controlled trial. Ann Intern Med 140: 786-794, 2004.

Harris M et al. Replacing a PI with efavirenz for management of PI toxicity. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 51, 1999.

Hatano H et al. Metabolic and anthropometric consequences of interruption of highly active antiretroviral therapy. AIDS 14: 1935-1942, 2000.

Havlir DV et al. Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression. AIDS (England) 15(11): 1379-1388, 2001.

Hengge UR et al. Randomized phase III trial of oxymetholone for the treatment of HIV wasting and lipodystrophy. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 705, 2002.

Henry K et al. ACTG5056: Metabolic status and cardiovascular disease risk for a cohort of HIV-1-infected persons durably suppressed on an indinavir-containing regimen (ACTG372A). Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 656, 2001.

Henry K et al. Lipid abnormalities associated with use of protease inhibitors: Prevalence, clinical sequalae and treatment. Twelfth World AIDS Conference, Geneva, abstract 12319, 1998a.

Henry K et al. Severe premature coronary artery disease with protease inhibitors. Lancet 351: 328, 1998b.

Henry K et al. Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities (research letter). Lancet 352(9133): 1031, 1998c.

Hewitt RG et al. Indinavir, not nelfinavir, is associated with systemic hypertension when compared to no protease inhibitor therapy. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 658, 2001.

Hewitt RG et al. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1-positive patients. AIDS 13(7): 868-869, 1999.

Hewitt R et al. Systemic hypertension associated with indinavir. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract 1148, 1999b.

Hillegrand M et al. Risk factors for lipodystrophy. Thirteenth International AIDS Conference, Durban, abstract B4247, 2000.

Hirschel B et al. Switching from protease inhibitors to efavirenz: difference in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort. AIDS 16(3): 381-385, 2002.

Ho TT et al. Indinavir-associated facial lipodystrophy in HIV-infected patients. AIDS Patient Care and STDs 13(1): 11-16, 1999.

Holmberg S et al. Protease inhibitor use and myocardial infarctions in ambulatory HIV-infected persons. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 698, 2002.

Hsue P et al. Increased atherosclerotic progression in patients with HIV: The role of traditional and immunological risk factors. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 139lb, 2003.

Iloeje UH et al. Protease inhibitor exposure and the increased risk of cardiovascular disease in HIV-infected patients. HIV Medicine 6: 37 - 44, 2005.

Ionescu G et al. Acylation stimulating protein (ASP) and tumor necrosis factor (TNF) production in subcutaneous adipose tissue of HIV-infected patients with and without lipodystrophy. Fourteenth International AIDS Conference, Barcelona, abstract WePeA5794, 2002.

Jacobson DL et al. Evolution of fat atrophy (FA) and fat deposition (FD) over 1 year in a cohort of HIV-infected men and women. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 685, 2002.

Jain RG et al. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. Journal of Biological Chemistry 277(22): 19247-19250, 2002.

Jaquet D et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 14: 2123-2128, 2000.

John M et al. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy. AIDS 15: 717-723, 2001.

John M et al. A randomised, controlled, open-label study of revision of antiretroviral regimens containing stavudine (d4T) and/or a protease inhibitor (PI) to zidovudine (ZDV)/lamivudine (3TC)/abacavir (ABC) to prevent or reverse lipoatrophy: 48-week data. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 700, 2002.

John M et al. Randomized, controlled, 48 week study of switching stavudine and/or protease inhibitors to Combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients. J Acquir Immune Defic Syndr 33: 29-33, 2003.

Johnson JA et al. Elevated in vitro tumour necrosis factor alpha release from abdominal subcutaneous adipose tissue in HIV-infected subjects with lipodystrophy. Antivir Ther 6: 16, 2001.

Johnson J et al. Studies of subcutaneous adipose tissue in HIV+ subjects with and without lipodystrophy. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7357, 2002.

Joly V et al. Assessment of lipodystrophy in patients previously exposed to AZT, ddI or ddC, but naive for d4T, and protease inhibitors, and randomised between d4T/3TC/indinavir and AZT/3TC/indinavir (NOVAVIR trial). Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 539, 2001.

Jones S et al. Short-term exercise training improves body composition and hyperlidemia in HIV-positive individuals with lipodystrophy. AIDS 15(15): 2049-2051, 2001.

Kakuda TN et al. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy. AIDS 13(16): 2311-2312, 1999.

Katlama C et al. Successful substitution of protease inhibitors with Sustiva (efavirenz) in patients with undetectable plasma HIV-1 RNA: results of a prospective, randomized, multicenter, open-label study (DMP 006-027). Thirteenth International AIDS Conference, Durban, abstract LB B7044, 2000.

Keithley JK et al. A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia. Nutrition 18(2): 201-204, 2002.

Keruly JC et al. Incidence of and factors associated with the development of hypercholesterolemia and hyperglycaemia in HIV-infected patients using a protease inhibitor. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract I-95, 1998.

Kingsley L et al. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS). Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 538, 2001.

Klein D et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? Journal of Acquired Immune Deficiency Syndromes 30(5): 471-477, 2002.

Knetchen H et al. Sustained viral suppression after substitution of efavirenz (EFV) for protease inhibitor (PI) in a regimen with lamivudine (3TC) and stavudine (d4T) or zidovudine (AZT). Thirteenth International AIDS Conference, Durban, abstract B4154, 2000.

Koppel K et al. Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 29(5): 441-449, 2002.

Koppel K et al. The ratio of visceral/subcutaneous adipose tissue has different implications in naive patients and patients on protease inhibitor containing highly active antiretroviral treatment. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7327, 2002b.

Kosmiski LA et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 15: 1993-2000, 2001.

Kotler DP et al. Studies of body composition and fat distribution in HIV-infected and control subjects. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 20(3): 228-237, 1999.

Kotler DP et al. Growth hormone (Serostim) effectively reduces visceral adipose tissue accumulation and non-HDL cholesterol. Fourteenth International AIDS Conference, Barcelona, abstract LbOr18, 2002.

Ladisa N et al. Efficacy and tolerability of switching from a protease inhibitor (PI)-containing regimen to PI-sparing non-nucleoside reverse transcriptase inhibit (NNRTI)-containing regimen in patients with undetectable viral load and metabolic disturbances. Thirteenth International AIDS Conference, Durban, abstract B4157, 2000.

Lafaurie M et al. Treatment of HIV-associated lipoatrophy of the face with intradermal injections of polylactic acid. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 704T, 2002.

Lallemand F et al. Sexual dysfunction in 156 ambulatory HIV-infected men receiving highly active antiretroviral therapy combinations with and without protease inhibitors. Journal of Acquired Immune Deficiency Syndromes 30(2): 187-190, 2002.

Laurenroth-Mai E et al. HIV-associated lipodystrophy syndrome:LioN-HAART Cohort:(lipodystrophy in patients on nucleoside-based HAART). Journal of Acquired Immune Deficiency Syndromes 31(2): 253-255, 2002.

Ledru E et al. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 95(10): 3191-3198, 2000.

Lemieux I et al. Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men. The Quebec Cardiovascular Study. Archives of Internal Medicine 161: 2685-2692, 2001.

Lenhard J et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Research 47(2): 121-129, 2000.

Lenhard Jet al. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arteriosclerosis, Thrombosis, and Vascular Biology 20(12): 2625-2629, 2000b.

Lenhard JM et al. Stimulation of vitamin A(1) acid signaling by the HIV protease inhibitor indinavir. Biochemical Pharmacology 59(9): 1063-1068, 2000c.

Liang JS et al. HIV protease inhibitors increase secretion of apolipoprotein B-lipoproteins from hepatoma cells by preventing proteasomal degradation. Antiviral Therapy 5 (Supp 5): 12, 2000.

Liang JS et al. HIV protease inhibitors protect apolipoprotein B from degradation by the proteasome: a potential mechanism for protease inhibitor-induced hyperlipidemia. Nature Medicine 7(12): 1327-1331, 2001.

Lichtenstein K et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 15(11): 1389-1398, 2001.

Lichtenstein K et al. Incidence and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 684, 2002.

Lipshultz SE et al. Absence of cardiac toxicity of zidovudine in infants. New England Journal of Medicine 343(11): 759-766, 2000.

Lipshultz SE et al. Cardiovascular status of infants and children of women infected with HIV-1 (P²C² HIV): a cohort study. Lancet 360(9330): 368-373, 2002.

Lister RK et al. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet 353(9165):1673, 1999.

Lloyd-Jones DM et al. The risk of congestive heart failure: sobering lessons from the Framingham Heart Study. Current Cardiology Reports 3(3): 184-190, 2001.

Lo JC et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. Journal of Clinical Endocrinology and Metabolism 86(8): 3480-3487, 2001.

Loignon M et al. L-carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults. AIDS 15(9): 1194-1195, 2001.

Lundgren JD et al. Perspective of HIV-associated coronary heart disease. Fourteenth International AIDS Conference, Barcelona, abstract WeOrB203, 2002.

Maggi P et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 14(16): F123-128, 2000.

Maggi P et al. Colour-Doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 18(7): 1023-8, 2004.

Maggiolo F et al. PI-associated metabolic changes: switch therapy with efavirenz in virologically controlled HIV+ persons. Thirteenth International AIDS Conference, Durban, abstract B 1484, 2000.

Magro DO et al. Effect of diet and exercise on HIV-associated hypertriglyceridemia. Third International Conference on Nutrition and HIV Infection, Cannes, abstract P-19, 1999.

Mahajan AP et al. Brief report: plateau in body habitus changes and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy: a 3.5-year study. Journal of Acquired Immune Deficiency Syndromes 28(4): 332-335, 2001.

Maher B et al. Lipodystrophy in patients with HIV-1 infection: effect of stopping protease inhibitors on TNF-receptor levels, insulin resistance, and lipid profile. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract P137A, 2000. AIDS 14(supp 4): P137A, 2000b.

Maher B et al. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16(15): 2013-8, 2002.

Mallal S et al. Light and electron microscopy findings in subcutaneous fat in antiretroviral treated naive HIV-infected patients. Thirteenth International AIDS Conference, Durban, abstract LB B7054, 2000.

Mallal S et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14: 309-1316, 2000.

Martin A et al. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study. AIDS 18: 1029-1036, 2004.

Martinez E et al. Reversion of metabolic abnormalities after switching HIV-1 protease inhibitors to nevirapine. AIDS 13(7): 805-810, 1999.

Martinez E et al. Sexual dysfunction with protease inhibitors. Lancet 353(9155): 810-811, 1999b.

Martinez E et al. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy. Clinical Infectious Diseases 31(5):1266-1273, 2000.

Martinez E et al. Risk of lipodystrophy in HIV-1 infected patients treated with protease inhibitors: a prospective cohort study. Lancet 357(9256): 592-598, 2001.

Martinez E et al. A randomized, double-blind, placebo-controlled, comparative study on the effects of metformin or gemfibrozil in lipodystrophic HIV-1-infected patients receiving protease inhibitors (PI). Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 702T, 2002.

Martinez E et al. Switching protease inhibitors to nevirapine (NEV), efavirenz (EFA) or abacavir (ABA): a randomized, multicenter, open-label, simplification trial. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract LB17, 2002b.

Martí®¥z-Garcí¡ T et al. Ventricular mass and diastolic function in patients infected by the human immunodeficiency virus. Heart 84(6): 620-624, 2000.

Mary-Krause M et al. Impact of treatment with protease inhibitor on myocardial infarction occurrence in HIV-infected men. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 657, 2001.

Maserati R et al. Intima media thickness as cardiovascular risk marker in HIV-positive patients treated and untreated with protease inhibitors. Antiviral Therapy 5 (Supp 5): 16, 2000.

Matetzky S et al. Acute myocardial infarction in human immunodeficiency virus-infected patients. Archives of Internal Medicine 163: 457-460, 2003.

Matheron S et al. Metabolic and clinical evaluation of lipodystrophy syndrome in HIV-1-infected adults receiving initial HAART with or without a protease inhibitor (PI): 48-week data from the CNAF3007 study. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 670, 2001.

Matthews GV et al. Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy. Journal of Acquired Immune Deficiency Syndromes 24(4): 310-315, 2000.

Mauss S et al. Reversal of protease inhibitor-related visceral abdominal fat accumulation with recombinant human growth hormone. Annals of Internal Medicine 131(4): 81-87, 1999.

Mauss S et al. L-Carnitine in the treatment of HIV-associated lipodystrophy syndrome. HIV Medicines 2(1): 59-60, 2001.

Mauss S et al. Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment. HIV Medicine 3(1): 49-55, 2002.

Mauss S et al. Rapid development of central adiposity after antiretroviral exposure - a proof of principle. Antiviral Therapy 7: L51 (abstract 77), 2002.

McComsey G et al. Analysis of the mitochondrial DNA genome in the peripheral blood leukocytes of HIV-infected patients with or without lipoatrophy. AIDS 16: 513-518, 2002.

McComsey G et al. Effect of ritonavir-boosted protease inhibitor regimens on lipid profiles. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7319, 2002b.

McComsey G et al. Improvements in lipoatrophy (LA) are observed after 24 weeks when stavudine (d4T) is replaced by either abacavir (ABC) or zidovudine (ZDV). Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 701T, 2002c.

McComsey G et al. Pretreatment leptin levels may predict risk of lipoatrophy while CD4 counts, tumour necrosis factor and on-treatment changes in these indices do not. Antivir Ther 7: L51(abstract 78), 2002d.

McComsey G et al. Extensive investigations of mitochondrial DNA genome in treated HIV-infected subjects: beyond mitochondrial DNA depletion. J Acquir Immune Defic Syndr 39: 181-188, 2005a.

McComsey GA et al. Effect of NucleoMaxX on fat and blood mitochondrial DNA in d4T-treated subjects with clinical lipoatrophy. Antivir Ther 10: L7, 2005b.

Mehta S et al. The effect of HAART and HCV infection on the development of diabetes mellitus. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 679, 2002.

Meneilly G et al. Metabolic and body composition changes in HIV-infected children on antiretroviral therapy. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 650, 2001.

Meng Q et al. Use of HIV protease inhibitors is associated with left ventricular morphologic changes and diastolic dysfunction. Journal of Acquired Immune Deficiency Syndromes 30(3): 306-310, 2002.

Mercie P et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Annals of Medicine 34(1): 55-63, 2002.

Meyers D et al. Risk factors for atherosclerosis in protease inhibitor experienced HIV patients with vascular complications. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, abstract 809, 1999.

Milano D et al. Two case reports of unusual lipomatous growth associated with combination antiretroviral therapy. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 42, 1999.

Miller J et al. The Australian lipodystrophy prevalence survey. Eleventh Annual Conference of the Australasian Society for HIV Medicine, Perth, abstract OR 104, 1999.

Miller J et al. Lipodystrophy following antiretroviral therapy of primary HIV infection. AIDS 14: 2406-2407, 2000.

Miller J et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. AIDS 16: 2195-2200, 2002.

Miro JM et al. Incidence of lipodystrophy in patients with primary HIV-1 infection (PHI) treated with HAART. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 12, 2000.

Miro O et al. Mitochondrial respiratory deficiency in antiretroviral therapy-related lipodystrophy. Fourteenth International AIDS Conference, Barcelona, abstract TuPeB4506, 2002.

Moerman F et al. Highly active antiretroviral therapy: cardiovascular risk needs to be assessed before starting treatment. Brit Med J 330: 1341-1342, 2005.

Mofenson LM. Perinatal Exposure to Zidovudine - Benefits and Risks (editorial). N Engl J Med 343: 803-805, 2000.

Morgello S et al. Mitochondrial abnormalities in human immunodeficiency virus-associated myopathy. Acta Neuropathologic (Berl) 90: 366-374, 1995.

Morlese JF et al. Interferon-alpha therapy increases plasma triglyceride concentations in HIV-1 seropositive patients. Fifth International Congress on Drug Therapy in HIV Infection, Glasgow, abstract P138, 2000. AIDS 14(supp 4): P138, 2000.

Morris A and Carr A. HIV nucleoside analogues: new adverse effects on mitochondria. Lancet 354(9184): 1046, 1999.

Moyle G et al. Body fat redistribution in persons on non-PI-containing regimens. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 53, 1999b.

Moyle GJ et al. Lipid abnormalities during saquinavir soft-gel-based highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes 21(5): 423-424, 1999e.

Moyle GJ. Mitochondrial toxicity hypothesis for lipoatrophy: a refutation. AIDS 15: 413-428. 2001.

Moyle GJ et al. Dietary advice with or without pravastatin for the management of hypercholesterolaemia associated with protease inhibitor therapy. AIDS 15(12): 1503-8, 2001b.

Moyle GJ et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: single-arm observational cohort. Journal of Acquired Immune Deficiency Syndromes 28(4): 399-401, 2001c.

Moyle GJ et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: relevance, reproducibility and possible risk factors. AIDS 16(10): 1341-1349, 2002.

Moyle GJ et al. Recombinant human growth hormone hormone is effective to treat HIV/AIDS associated wasting in the era of highly active anti-retroviral therapy. Fourteenth International AIDS Conference, Barcelona, abstract LbPeB9012, 2002c.

Moyle GJ et al. Polylactate (NewFill) injections subjectively and objectively improve appearance and reduce anxiety and depression scores in HIV-positive persons with facial lipoatrophy: a randomised, open label, immediate vs. delayed therapy study. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract H-1934, 2002d.

Moyle GJ et al. A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 5(2):82-7, 2004.

Moyle GJ et al. A 48 week, randomized, open label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy. Journal of Acquired Immune Deficiency Syndromes 33: 22-28, 2003.

Moyle GJ and Sutinen J. Managing HIV lipoatrophy - commentary. Lancet 363 (9407): 412-414 2004.

Mukhopadhyay A et al. In vitro evidence of inhibition of mitochondrial protease processing by HIV-1 protease inhibitors in yeast: a possible contribution to lipodystrophy syndrome. Mitochondrion 2 (Sept): 54-62, 2002.

Mulligan K et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. Journal of Acquired Immune Deficiency Syndromes 23(1): 35-43, 2000.

Mulligan K et al. Fat distribution in HIV-infected women in the United States: DEXA substudy in the Womens Interagency HIV Study. J Acquir Immune Defic Syndr 38: 18 22, 2004.

Munch-Petersen B et al. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. Journal of Biological Chemistry 266: 9032-9038, 1991.

Munsiff AV et al. Undiagnosed antecedent hyperglycemia in HIV-positive adults treated with protease inhibitors. International Conference on the Discovery and Clinical Development of Antiretroviral Therapies, Virgin Islands, abstract LB3, 1998.

Murata H et al. The mechanism of insulin resistance caused by HIV protease inhibitor therapy. Journal of Biological Chemistry275(27): 20251-20254, 2000.

Murata H et al. Inhibition of cellular glucose uptake by indinavir. Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV in: Antiviral Therapy 6: (supp4): 3, 2001.

Murphy R et al. Switching to thymidine analog-sparing or a nucleoside-sparing regimen improves lipoatrophy: 24-week results of a prospective randomized clinical trial, AACTG 5100. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 45LB, 2005.

Muurahainen N et al. Gender differences in HIV-associated adipose redistribution syndrome (HARS): an update. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 26, 2000.

Muurahainen N et al. Different factors are associated with abnormal fat accumulation and fat depletion in men and women with HIV. Antiviral Therapy 5 (Supp 5): 65, 2000.

Mynarcik DC et al. Association of severe insulin resistance with both loss of limb fat and elevated serum tumour necrosis factor receptor levels in HIV lipodystrophy. Journal of Acquired Immune Deficiency Syndromes 25: 312-321, 2000.

Nauss-Karol C et al. Changes in serum lipids in HIV-infected patients treated with HAART regimens containing one or two protease inhibitors. Fourth Congress on Drug Therapy in HIV Infection, Glasgow, abstract P143, 1998.

Negredo E et al. Muscle biopsies to identify mitochondrial toxicity (MT) in HIV-1-infected patients. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, abstract 66, 2001.

Negredo E et al. Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 16(10): 1383-1389, 2002.

Negredo E et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases 34(4): 504-510, 2002b.

Negredo E et al. Impact of pravastatin on dyslipidemia induced by antiretroviral therapy. Fourteenth International AIDS Conference, Barcelona, abstract TuPeB4518, 2002c.

Nelson MR et al. The incidence of hyperlipidemia with protease inhibitors. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract I-87, 1998.

Nolan D et al. Getting to the HAART of insulin resistance (editorial comment). AIDS 15: 2037-2041, 2001.

Nolan D et al. Tumour necrosis factor alpha gene-238G/A promoter polymorphism associated with more rapid onset of lipodystrophy. Antiviral Therapy 7: L17 (abstract 26), 2002.

Nolan D et al. Effect of stavudine, zidovudine and HIV protease inhibitor therapy on subcutaneous leg fat wasting in HIV-infected males - a longitudinal study. Antiviral Therapy 7: L18 (abstract 28), 2002.

Nolan D et al. Differential effects of nucleoside reverse transciptase inhibitor (NRTI) regimens on adipocyte mitochondrial DNA depletion in HIV-infected patients. Antivir Ther 9: L11, 2004.

Noor MA et al. Metabolic effects of indinavir in healthy HIV-seronegative men. AIDS 15:11-18, 2001.

Noor MA et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 16(5): F1-F8, 2002.

O'Moore OJ et al. Lipid perturbation: a protease inhibitor-specific problem? Fifth Annual Meeting of the British HIV Association, Cambridge, abstract 18, 1999.

Opravil M et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis 185(9): 1251-60, 2002.

Oral EA et al. Leptin-replacement therapy for lipodstrophy. New England Journal of Medicine 346(8): 570-578, 2002.

Para M et al. Treatment with delavirdine in combination with NRTIs and/or PIs is not associated with lipodystrophy or metabolic lipid/glucose disturbances. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 66, 1999.

Pariset C et al. Cardiovascular disease in HIV-patients under HAART: metabolic disorders in question. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract 1133, 1999.

Patroni A et al. Sexual dysfunctions in HAART treated HIV+ patients. Thirteenth International AIDS Conference, Durban, abstract B4243, 2000.

Peabody D et al. The triglyceride-lowering effect of omega-3 fatty acids in HIV-infected patients on HAART. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7342, 2002.

Pedneault L et al. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection. Clinical Therapy 22(12): 1378-1394, 2000.

Periard D et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 100(7): 700-705, 1999.

Pernerstorfer-Schoen HE et al. Beneficial effects of protease inhibitors on body composition and energy expenditure: a comparison between HIV-infected and AIDS patients. AIDS 13(17): 2389-2396, 1999.

Pernerstorfer-Schoen HE et al. Sex differences in HAART-associated dyslipidemia. AIDS 15: 725-34, 2001.

Petit JM et al. HIV-1 protease inhibitors induce an increase of triglyceride level in HIV-infected men without modification of insulin sensitivity: a longitudinal study. Hormonal and Metabolic Research 32(9): 367-72, 2000.

Petit JM et al. LDL-receptors expression in HIV-infected patients: relations to antiretroviral therapy, hormonal status, and presence of lipodystrophy. European Journal of Clinical Investigation 32(5): 354-359, 2002.

Peyriere H et al. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection. AIDS 13(15): 2167-2169, 1999.

Piliero P et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile: results of clinical trials beyond week 48. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 706T, 2002.

Pinto AN et al. AIDS and cerebrovascular disease. Stroke 27(3): 538-543, 1996.

Piroth L et al. Simplified maintenance therapy with NNRTI (nevirapine) in patients with long term suppression of HIV-1 RNA: first results of a cohort study. Thirteenth International AIDS Conference, Durban, abstract B4167, 2000.

Poizot-Martin I et al. Follow up of glucose metabolism in a cohort of HIV infected patients with HAART. Fourteenth International AIDS Conference, Barcelona, abstract TuPeB4530, 2002.

Pollner J et al. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors. Twelfth World AIDS Conference, Geneva, abstract 12269, 1998.

Polo R et al. Lipoatrophy, fat accumulation, and mixed syndrome in protease inhibitor-naive HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 25(3): 284-286, 2000.

Ponce-de-Leon S et al. Liposuction for protease-inhibitor-associated lipodystrophy (Research letter). Lancet 353(9160):1244, 1999.

Pujari SN et al. Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in western India. J Acquir Immune Defic Syndr 39: 199-202, 2005.

Qazi NM et al. Diagnosis and management of male breast enlargement in patients with HIV/AIDS. AIDS Reader 10(12): 703-708, 2000.

Rachlis A et al. Successful substitution of protease inhibitors with SUSTIVA (efavirenz) in patients with undetectable plasma HIV-1 RNA levels - results of a prospective, randomized, multicenter, open-label study (DMP 266-049). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, abstract 475, 2000.

Raffi F et al. Substitution of a nonnucleoside reverse transcriptase inhibitor for a protease inhibitor in the treatment of patients with undetectable plasma human immunodeficiency virus type 1 RNA. Clinical Infectious Diseases 31(5): 1274-1278, 2000.

Rakotoambinina B et al. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. Journal of Acquired Immune Deficiency Syndromes 27(5): 443-449, 2001.

Reitman M. The physiology of lipoatrophy. Antiviral Therapy 5 (Supp 5):3, 2000.

Rey D et al. Current status of the Strasbourg efavirenz cohort: EFV as a substitute for protease inhibitor in patients on triple drug therapy with plasma viral load below 50 copies/ml. Seventh European Conference on Clinical Aspects and Treatment of HIV-Infection, Lisbon, abstract 596, 1999.

Rey D et al. Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. Journal of Acquired Immune Deficiency Syndromes 27(5): 459-462, 2001.

Rietschel P et al. Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy. Journal of Clinical Endocrinology and Metabolism 86(2): 504-510, 2001.

Roca B et al. HAART with efavirenz: metabolic and hepatic side effects. Fourteenth International AIDS Conference, Barcelona, abstract TuPeB4503, 2002.

Roche R et al. Effects of antiretroviral drug combinations on the differentiation of adipocytes. AIDS 16(1): 13-20, 2002.

Rodo MS et al. Hyperglycaemia associated with protease inhibitor therapy. Twelfth World AIDS Conference, Geneva, abstract 12387, 1998.

Roge BT et al. Mitochondrial function in HIV-infected patients with lipodystrophy during exercise and recovery. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, abstract P22, 2000.

Roge BT et al. Comparison of P-triglyceride levels among patients with human immunodeficiency virus on randomized treatment with ritonavir, indinavir or ritonavir/saquinavir. Scandinavian Journal of Infectious Diseases 33(4): 306-11, 2001.

Roth VR et al. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clinical Infectious Diseases 27(1): 65-67, 1998.

Rothstein AM et al. Investigation of protease inhibitor-associated lipodystrophy in HIV-infected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract I-91, 1998.

Rottman C et al. Virological response to a once daily protease inhibitor sparing regimen (ddI, 3TC, NVP) after successful PI containing regimen. Fourth International congress on Drug Therapy in HIV Infection, Glasgow, abstract PO 2.1, 1998.

Roubenoff R et al. Reduction of abdominal obesity in lipodystrophy associated with human immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clinical Infectious Diseases 34(3): 390-393, 2002.

Ruiz L et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndromes 27(3): 229-236, 2001.

Saint-Marc T et al. Buffalo hump in HIV-1 infection. Lancet 352: 9124, July 25 1998.

Saint-Marc T et al. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy. AIDS 13(15): 2188-2189, 1999.

Saint-Marc T et al. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 13(8): 1000-1002, 1999a.

Saint-Marc T et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 13(13): 1659-1667, 1999d.

Saint-Marc T et al. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 14(1): 37-49, 2000.

Sattler FR et al. Elevated blood pressure in subjects with lipodystrophy. AIDS 15(15): 2001-2010, 2001.

Saves M et al. Incidence of lipodystrophy and glucose and lipid abnormalities during the follow-up of a cohort of HIV-infected patients started on a protease inhibitor (PI)-containing regimen. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract 682, 2002.

Saves M et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clinical Infectious Diseases 34(10): 1396-1405, 2002b.

Schliefer K et al. Efficacy of bezafibrate in the treatment of PI-induced hyperlipidaemia - 36 weeks data. 13th International AIDS Conference, Durban, 2000.

Schmitz M et al. Alterations of apolipoprotein B metabolism in HIV-infected patients with antiretroviral combination therapy. Journal of Acquired Immune Deficiency Syndromes 26(3): 225-235, 2001.

Schrooten W et al. Sexual dysfunction associated with protease inhibitor containing highly active antiretroviral treatment. AIDS 15(8): 1019-1023, 2001.

Sekhar RV et al. Dysregulation of lipid turnover is a key defect in the lipodystrophy syndrome. Second International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, abstract P24, 2000.

Seminari E et al. Haemostatic markers of cardiovascular risk in HIV patients treated and untreated with protease inhibitors. Thirteenth International AIDS Conference, Durban, abstract B760, 2000.

Seminari E et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 162(2): 433-438, 2002.

Serra M. Facial implants with polymethyl-methylcrylate for lipodystrophy correction: 30 months follow up. Antiviral Therapy 6 (Supp 4): 75, 2001.

Serra M. Subcutaneous infiltration with phosphatidylcholine solution for treatment of buffalo hump and fatty pads. Antiviral Therapy 6 (Supp 4): 75-76, 2001.

Shepherd J et al for the West of Scotland Coronary Prevention Study Group. Prevention of coronary disease with pravastatin in men with hypercholesterolemia. New England Journal of Medicine 333(2): 1301-1307, 1995.

Shervitz A et al. DXA analysis of the association between protease inhibitor use and fat distribution in HIV-infected adults. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 27, 1999.

Shikuma C et al. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy. AIDS 15(14): 1801-1809, 2001.

Shimomura I et al. Lessons from lipodystrophic mice - a vicious circle in metabolism. Antiviral Therapy 5 (Supp 5): 3, 2000.

Silva M et al. The effect of protease inhibitors on weight and body composition in HIV-infected patients. AIDS 12(13): 1645-1651, 1998.

Simon GL et al. Antiretroviral therapy-induced changes in lipoprotein subclass phenotype: comparison of protease inhibitor and non-nucleoside reverse transcriptase inhibitor regimens. Antiviral Therapy 7: L9 (abstract 14), 2002.

Simpson DM et al. Myopathies associated with human immunodeficiency virus and zidovudine: can their effects be distinguished? Neurology 43: 971-976, 1993.

Skolnik P et al Serum lipid levels in HIV-positive adults during saquinavir-containing combination therapy. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 35, 1999.

Solages A et al. Endothelial function in HIV-infected persons. Clin Infect Dis 42: 1325-1332, 2006.

Sollima S et al. Protease inhibitors and erectile dysfunction. AIDS 15(17): 2331-2333, 2001.

Stanworth SJ et al. Increased bleeding in HIV-positive haemophiliacs treated with antiretroviral protease inhibitors. Haemophilia 4:109-114, 1998.

Staszewski S et al. Efficacy and safety of tenofovir disoproxil fumarate versus stavudine (d4T) when used in combination with lamivudine (3TC) and efavirenz in HIV-1 infected patients naﶥ to antiretroviral therapy: 48 week results. Fourteenth International AIDS Conference, Barcelona, abstract LbOr17, 2002.

Staszewski S et al. Efficacy and safety of tenofovir DF versus stavudine when used in combination with lamivudine and efavirenz in antiretroviral naﶥ patients: preliminary interim 96 week results. Tenth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 564b, 2003.

Stein JH et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 104: 257-262, 2001.

Stein JH et al. Effects of pravastatin on lipids and lipoprotein sub-fractions in patients receiving HIV protease inhibitors. Antiviral Therapy 7: L34, 2002.

Stevens GJ et al. Preclinical investigations into the mechanism by which HIV protease inhibitors may induce metabolic disorders. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, abstract 1288, 1999.

Stevens GJ et al. Inhibition of adipocyte differentiation by HIV-1 protease inhibitors: potential mechanisms based on changes in gene expression. Antivir Ther 5: S26, 2000.

Sullivan PS et al. Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 14: 321-324, 2000.

Sutinen J et al. Rosiglitazone in the treatment of HAART-associated lipodystrophy (HAL): a randomized, double-blind, placebo-controlled study. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, abstract LB13, 2002a.

Sutinen J et al. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 16: 2183-2193, 2002b.

Sutinen J et al. Uridine supplementation increases subcutaneous fat in patients with HAART-associated lipodystrophy: a randomised placebo-controlled trial. Antivir Ther 10: L7, 2005.

Tai VW et al. Effects of recombinant human growth hormone on fat distribution in patients with human immunodeficiency virus-associated wasting. Clin Infect Dis 35: 1258-1262, 2002.

Talwani R et al. Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy. J Acquir Immune Defic Syndr 30: 191-195, 2002.

Tantisiriwat W et al. Elevated lactate levels in hospitalized persons with HIV infection. AIDS Res Hum Retroviruses 17: 195-201, 2001.

Tashima KT et al. Restoration of normal fat distribution in women 16-26 months after switch from protease inhibitor to non-nucleoside reverse transcriptase inhibitor based HAART. Fourteenth International AIDS Conference, Barcelona, abstract TuPeB4504, 2002.

Taskinen M et al. Impaired glucose tolerance and dyslipidemia as late effects after bone marrow transplantation in childhood. Lancet 356: 993-997, 2000.

Tebas P et al. A prospective open label pilot trial of a maintenance nevirapine (NVP)-containing regimen in patients with undetectable viral loads (VL) on protease inhibitor (PI) regimens for at least 6 months. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 45, 2000.

Tebas P et al. Evolution of multiple metabolic parameters after the switch of protease inhibitors to nevirapine. Thirteenth International AIDS Conference, Durban, abstract B1485, 2000.

Tebas P et al. Switch to a protease inhibitor containing/nucleoside reverse transcriptase inhibitor-sparing regimen increases appendicular fat and serum lipid levels without affecting glucose metabolism or bone mineral density. The results of a prospective randomised trial, ACTG 5125s. Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, abstract 40, 2005.

Tellol LM et al. Alterations in lipid metabolism and lipodystrophy related to HIV in infected children. Fourteenth International AIDS Conference, Barcelona, abstract TuPeB4531, 2002.

Tenzif S et al. A study of the effectiveness of regular exercise on lean body mass, body cell mass and quality of life in people living with HIV/AIDS. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 59, 1999.

Thiebaut R et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France, 1999. Groupe d'Epidemiologie Clinique du Syndrome d'Immunodeficience Acquise en Aquitaine. Clinical Infectious Diseases 31(6): 1482-1487, 2000.

Torti C et al. Influence of hepatitis C virus coinfection on lipid abnormalities in HIV-positive patients after highly active antiretroviral therapy. Journal of AIDS 29(3): 315-317, 2002.

Van Leth et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naﶥ patients infected with HIV-1. PLoS Med 1: e19, 2004.

Van der Valk M et al. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection. AIDS 15: 847-855, 2001a.

Van der Valk M et al. Lipodystrophy in HIV-1-positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 15: 2093-2100, 2001b.

Van der Valk M et al. Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 15(18): 2407-2414, 2001c.

Van Wijk JPH et al. Comparison of rosiglitazone and metformin for treating HIV lipodystrophy. Ann Intern Med 143: 337 346, 2005.

Veny A et al. Cumulative risk for developing protease inhibitor-associated lipodystrophy (PI-AL) in HIV-infected patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, abstract I-92, 1998.

Viciana P et al. Partial improvement of lipodystrophy after switching from HIV-1 protease inhibitors (PI) to efavirenz (EFV). Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 48, 2000.

Visnegarwala F et al. Inconsistent effects of lipid-lowering drugs in the management of HIV-associated dyslipidemias. Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, abstract 30, in Antiviral Therapy 6(suppl 4): 21-22, 2001.

Visnegarwala F et al. Use of PPAR-gamma modulator rosiglitazone in normoglycemic patients with HIV lipodystrophy syndrome. Third International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Athens, abstract 124, in Antiviral Therapy 6(suppl 4): 82, 2001.

Walker UA et al. Evidence of nucleoside analogue reverse transcriptase inhibitor--associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 29(2): 117-121, 2002.

Walker UA et al. Increased long-term mitochondrial toxicity of nucleoside analogue reverse-transcriptase inhibitors. AIDS 16(16): 2165-2174, 2002b.

Walmsley S et al. A prospective study of body fat redistribution and metabolic abnormalities in patients initiating highly active antiretroviral therapy. Antiviral Therapy 7: L54 (abstract 82), 2002.

Walli R et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 12: F167-F174, 1998.

Walli R et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Research into Experimental Medicine (Berl) 199(5): 253-262, 2000.

Wanke C et al. Prevalence of fat deposition and fat atrophy in a cohort of HIV-infected men and women. Seventh Conference on Retroviruses and Opportunistic Infections, San Francisco, abstract 24, 2000.

Ware LJ et al. Differences in postprandial lipid metabolism in patients with PI-associated and NRTI-associated lipodystrophy. Antiviral Therapy 5 (Supp 5): 13, 2000.

Weber R et al. Risks for cardiovascular disease (CVD) associated with antiretroviral therapy (ART). 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, abstract I-1326, 2001.

Whetam J et al. Cardiovascular risk factors in HIV-infected patients receiving protease inhibitors. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7392, 2002.

Wit FWNM et al. Stavudine use is not associated with an incremental risk of hyperlipidaemia during treatment with HIV-1 protease inhibitors. First International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, abstract 65, 1999.

Wolf E et al. Estradiol levels and lipodystrophy in HIV+ men. Thirteenth International AIDS Conference, Durban, abstract B 1382, 2000.

Wood R et al. Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir. J Acquir Immune Defic Syndr 36: 684 - 692, 2004.

Woolley IJ et al. Cardiovascular events in the MACS cohort and prior prophylaxis with macrolides for mycobacterium avium complex. Fourteenth International AIDS Conference, Barcelona, abstract ThPeB7282, 2002.

Yarasheski EK et al. Resistance exercise training reduces hypertriglyceridemia in HIV-infected men treated with antiviral therapy. Journal of Applied Physiology 90(1): 133-138, 2001.

Yoon C et al. Case-control study of diabetes mellitus in HIV-infected patients. JAIDS 37 (4); 1464-1469, 2004.

Youle M et al. Lipid profiles in patients on ritonavir/indinavir-containing salvage regimens. Second International Workshop on Salvage Therapy for HIV Infection, Toronto, abstract 24, 1999.